Effective osteoporosis treatment with teriparatide is associated with enhanced quality of life in postmenopausal women with osteoporosis: the European Forsteo Observational Study

Hdl Handle:
http://hdl.handle.net/10147/302728
Title:
Effective osteoporosis treatment with teriparatide is associated with enhanced quality of life in postmenopausal women with osteoporosis: the European Forsteo Observational Study
Authors:
Ljunggren, Östen; Barrett, Annabel; Stoykov, Ivaylo; Langdahl, Bente L; Lems, Willem F; Walsh, J B; Fahrleitner-Pammer, Astrid; Rajzbaum, Gerald; Jakob, Franz; Karras, Dimitrios; Marin, Fernando
Citation:
BMC Musculoskeletal Disorders. 2013 Aug 22;14(1):251
Issue Date:
22-Aug-2013
URI:
http://dx.doi.org/10.1186/1471-2474-14-251; http://hdl.handle.net/10147/302728
Abstract:
Abstract Background To describe changes in health-related quality of life (HRQoL) of postmenopausal women with osteoporosis treated with teriparatide for up to 18 months and followed-up for a further 18 months, and to assess the influence of recent prior and incident fractures. Methods The European Forsteo Observational Study (EFOS) is an observational, prospective, multinational study measuring HRQoL using the EQ-5D. The primary objective was to assess changes in HRQoL during 36 months in the whole study population. A secondary post-hoc analysis examined fracture impact on HRQoL in four subgroups classified based on recent prior fracture 12 months before baseline and incident clinical fractures during the study. Changes from baseline were analysed using a repeated measures model. Results Of the 1581 patients, 48.4% had a recent prior fracture and 15.6% of these patients had an incident fracture during follow-up. 10.9% of the 816 patients with no recent prior fracture had an incident fracture. Baseline mean EQ-VAS scores were similar across the subgroups. In the total study cohort (n = 1581), HRQoL (EQ-VAS and EQ-5D index scores) improved significantly from baseline to 18 months and this improvement was maintained over the 18-month post-teriparatide period. Improvements were seen across all five EQ-5D domains during teriparatide treatment that were maintained after teriparatide was discontinued. Subjects with incident clinical fractures had significantly less improvement in EQ-VAS than those without incident fractures. Recent prior fracture did not influence the change in EQ-VAS during treatment. Conclusions EFOS is the first longitudinal study in women with severe postmenopausal osteoporosis in the real world setting to show a substantial improvement in HRQoL during teriparatide treatment that was sustained during subsequent treatment with other medications. The increase in HRQoL was lower in the subgroups with incident fracture but was not influenced by recent prior fracture. The results should be interpreted in the context of the design of an observational study.
Item Type:
Article
Language:
en
Keywords:
OSTEOPOROSIS

Full metadata record

DC FieldValue Language
dc.contributor.authorLjunggren, Östenen_GB
dc.contributor.authorBarrett, Annabelen_GB
dc.contributor.authorStoykov, Ivayloen_GB
dc.contributor.authorLangdahl, Bente Len_GB
dc.contributor.authorLems, Willem Fen_GB
dc.contributor.authorWalsh, J Ben_GB
dc.contributor.authorFahrleitner-Pammer, Astriden_GB
dc.contributor.authorRajzbaum, Geralden_GB
dc.contributor.authorJakob, Franzen_GB
dc.contributor.authorKarras, Dimitriosen_GB
dc.contributor.authorMarin, Fernandoen_GB
dc.date.accessioned2013-10-04T15:08:08Z-
dc.date.available2013-10-04T15:08:08Z-
dc.date.issued2013-08-22-
dc.identifier.citationBMC Musculoskeletal Disorders. 2013 Aug 22;14(1):251en_GB
dc.identifier.urihttp://dx.doi.org/10.1186/1471-2474-14-251-
dc.identifier.urihttp://hdl.handle.net/10147/302728-
dc.description.abstractAbstract Background To describe changes in health-related quality of life (HRQoL) of postmenopausal women with osteoporosis treated with teriparatide for up to 18 months and followed-up for a further 18 months, and to assess the influence of recent prior and incident fractures. Methods The European Forsteo Observational Study (EFOS) is an observational, prospective, multinational study measuring HRQoL using the EQ-5D. The primary objective was to assess changes in HRQoL during 36 months in the whole study population. A secondary post-hoc analysis examined fracture impact on HRQoL in four subgroups classified based on recent prior fracture 12 months before baseline and incident clinical fractures during the study. Changes from baseline were analysed using a repeated measures model. Results Of the 1581 patients, 48.4% had a recent prior fracture and 15.6% of these patients had an incident fracture during follow-up. 10.9% of the 816 patients with no recent prior fracture had an incident fracture. Baseline mean EQ-VAS scores were similar across the subgroups. In the total study cohort (n = 1581), HRQoL (EQ-VAS and EQ-5D index scores) improved significantly from baseline to 18 months and this improvement was maintained over the 18-month post-teriparatide period. Improvements were seen across all five EQ-5D domains during teriparatide treatment that were maintained after teriparatide was discontinued. Subjects with incident clinical fractures had significantly less improvement in EQ-VAS than those without incident fractures. Recent prior fracture did not influence the change in EQ-VAS during treatment. Conclusions EFOS is the first longitudinal study in women with severe postmenopausal osteoporosis in the real world setting to show a substantial improvement in HRQoL during teriparatide treatment that was sustained during subsequent treatment with other medications. The increase in HRQoL was lower in the subgroups with incident fracture but was not influenced by recent prior fracture. The results should be interpreted in the context of the design of an observational study.-
dc.language.isoenen
dc.subjectOSTEOPOROSISen_GB
dc.titleEffective osteoporosis treatment with teriparatide is associated with enhanced quality of life in postmenopausal women with osteoporosis: the European Forsteo Observational Studyen_GB
dc.typeArticleen
dc.language.rfc3066en-
dc.rights.holderÖsten Ljunggren et al.; licensee BioMed Central Ltd.-
dc.description.statusPeer Reviewed-
dc.date.updated2013-10-01T19:31:08Z-
All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.